Introduction 

The third quarter of 2026 underscored just how rapidly the biopharma landscape is being reshaped by capital, innovation, and strategic consolidation. Across July through September, the industry saw a succession of multibillion-dollar acquisitions, high-value licensing agreements, and a broad spectrum of FDA approvals spanning oncology, rare diseases, metabolic disorders, neurology, immunology, and precision diagnostics. 

M&A activity remained a major force, with pharmaceutical and life sciences companies pursuing assets and platforms that could strengthen their positions in high-growth therapeutic areas. At the same time, licensing and research collaborations demonstrated that companies are increasingly willing to access external innovation rather than rely solely on internal pipelines. 

The quarter also delivered a diverse FDA approval landscape, ranging from novel therapies and accelerated approvals to imaging agents and treatments for rare and underserved diseases. 

Against this backdrop, Q3 2026 was less about incremental expansion and more about strategic positioning. Companies were making significant bets on technologies, platforms, and therapeutic assets that could define the next phase of biopharma growth. 

M&A: Biopharma Doubles Down on Strategic Assets 

The third quarter witnessed an extraordinary breadth of M&A activity, with transactions spanning therapeutics, radiopharmaceuticals, biotechnology, diagnostics, medical imaging, manufacturing, and healthcare technology. 

From Vertex Pharmaceuticals’ proposed acquisition of Crinetics Pharmaceuticals for approximately $10 billion to Novartis’ planned acquisition of Myricx Bio for approximately $1.5 billion, large-cap pharmaceutical companies continued to deploy significant capital to reinforce their pipelines. 

Among the other notable transactions, Ipsen agreed to acquire Memo Therapeutics for more than €700 million, while United Therapeutics moved to acquire Thymmune Therapeutics for approximately $300 million. Eli Lilly announced acquisitions of AtaiBeckley and Merida Biosciences for approximately $3.8 billion and $2.875 billion, respectively. 

The quarter also featured substantial activity beyond traditional pharmaceutical M&A. Curium and Lantheus announced an approximately $8 billion merger, while KKR agreed to acquire Integer for approximately $5.7 billion. Samsung Biologics announced its acquisition of PolyPeptide for approximately $1.8 billion, further highlighting the strategic importance of biopharmaceutical manufacturing capabilities. 

Radiopharma and imaging also emerged as prominent areas of consolidation. Telix Pharmaceuticals agreed to acquire ITM in a transaction valued at approximately $1.65 billion, while Teledyne announced its $1.1 billion acquisition of Varex Imaging. 

Other major transactions included: 

• Tempus AI’s approximately $1.5 billion acquisition of Personalis  

• Repligen’s approximately $1.5 billion acquisition of BioLife  

• Dassault Systèmes’ approximately $2 billion acquisition of ArisGlobal  

• argenx’s approximately $2.2 billion acquisition of Forte Biosciences  

• KKR’s approximately $5.7 billion acquisition of Integer  

• Tarsus Pharmaceuticals’ approximately $800 million acquisition of Alkeus Pharmaceuticals  

• Jazz Pharmaceuticals’ approximately $1.32 billion acquisition of Actio Biosciences  

Editor’s Take 

Q3’s M&A activity reveals an increasingly targeted approach to capital deployment. Rather than focusing exclusively on scale, buyers are pursuing differentiated assets, emerging platforms, manufacturing capabilities, diagnostics, and technologies that can complement existing commercial and R&D infrastructure. 

The prominence of radiopharmaceuticals, precision medicine, AI-enabled diagnostics, rare diseases, and specialized therapeutic platforms is particularly notable. The quarter suggests that strategic buyers continue to view differentiated technology and pipeline depth as important sources of long-term growth. 

Deals: Licensing Becomes a Major Engine of Innovation 

If M&A demonstrated the industry’s appetite for strategic acquisitions, Q3’s licensing and collaboration activity showed that companies are equally willing to access innovation through partnerships. 

The quarter produced numerous billion-dollar and multibillion-dollar deals across oncology, immunology, cardiovascular and renal medicine, neuroscience, RNA therapeutics, ADCs, bispecific antibodies, and long-acting drug delivery. 

CSPC Group and AstraZeneca entered a partnership to develop siRNA drugs in a deal valued at approximately $1.77 billion, while AstraZeneca also signed an exclusive licensing agreement with Sino Biopharmaceutical for TQC3721 worth approximately $1.9 billion. 

AstraZeneca further strengthened its external innovation portfolio through a global exclusive license agreement with Dizal for Zegfrovy, valued at approximately $1.5 billion. 

Roche was similarly active, with major transactions including: 

• Hanmi Pharmaceutical’s licensing of HM17321 to Genentech in a deal worth approximately $2.3 billion  

• Pathos AI’s approximately $2.2 billion licensing deal with Alphamab Oncology for JSKN016  

• DualityBio’s $1 billion+ agreement with Genentech to develop next-generation ADCs  

• Simcere Zaiming’s approximately $1.53 billion licensing agreement with Roche for SIM0660  

• Dualitas Therapeutics and Roche’s approximately $1 billion collaboration focused on novel bispecific antibodies for inflammatory and immunological diseases  

• Atavistik Bio’s approximately $1.97 billion partnership with Roche to advance allosteric small molecules for cardiovascular, renal, and metabolic diseases  

• Earendil Labs’ $1.5 billion+ research collaboration with Genentech focused on bispecific antibodies in oncology  

Other major transactions highlighted the breadth of external innovation: 

• Innovent Biologics licensed SP001 (IBI355) to Spero Therapeutics in a deal worth approximately $1.1 billion  

• Haisco licensed a preclinical immunology drug to Sentivera in a deal valued at $1.5 billion+  

• Biohaven licensed its Kv7 epilepsy platform to SK Biopharmaceuticals for approximately $795 million  

• GSK licensed HUTCHMED’s HMPL-A830 outside Greater China in a deal worth approximately $1.295 billion  

• Orbis Medicines and Novo partnered on oral macrocycle drugs in a deal valued at approximately $1.4 billion  

• BoomRay entered a deal worth approximately $900 million with Novartis for a novel radioligand therapy asset  

• Envisagenics and Boehringer Ingelheim signed a $1 billion+ cancer drug development agreement  

• InnoCare partnered with Eli Lilly in a drug development deal worth approximately $3.35 billion  

• Nanexa and Novo entered an approximately €1.165 billion deal focused on long-acting injectables  

• Merck and SciBrunch signed an approximately $2.13 billion exclusive global licensing agreement for SPR2015  

• AlzeCure partnered with QuantumCell for NeuroRestore ACD856 in a deal worth up to $2.2 billion  

Bayer also received €3 billion in equity capital from Apollo Investment, adding another dimension to the quarter’s financing activity. 

Editor’s Take 

The sheer number and scale of Q3 licensing agreements point toward an increasingly networked biopharma innovation model. 

Large pharmaceutical companies are not necessarily required to own every technology they need. Instead, licensing allows them to access promising assets, platforms, and scientific capabilities while potentially reducing the time and resources required to build those capabilities internally. 

The concentration of deals around ADCs, bispecific antibodies, siRNA, macrocycles, radioligand therapies, and long-acting formulations also highlights where strategic interest is concentrating. 

Importantly, the quarter demonstrates that innovation is increasingly being distributed across the ecosystem, with emerging biotech companies serving as sources of technologies that larger pharmaceutical organizations can scale globally. 

FDA Approvals: A Diverse Pipeline Reaches Patients 

The FDA approval landscape during Q3 2026 reflected the breadth of modern drug development, with approvals spanning oncology, rare diseases, neurology, metabolic disorders, ophthalmology, immunology, and diagnostic imaging. 

July 2026 

July opened the quarter with approvals and regulatory actions across several therapeutic categories. 

The FDA granted accelerated approval to Trutakna to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. 

The agency also approved Revtorpyk for HR-positive, HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer following progression after at least one line of endocrine therapy in the metastatic setting. 

Other July approvals included: 

• Lipfendra (20 mg, oral) as an adjunct to lifestyle intervention to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia  

• Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer following prior ROS1 kinase inhibitor treatment  

• Lytenava (bevacizumab-vikg) for wet age-related macular degeneration  

• Simtriyo (centanafadine) for ADHD in patients aged six years and older and weighing at least 20 kg, with availability expected following DEA scheduling  

August 2026 

August brought approvals across sleep disorders, Alzheimer’s disease diagnostics, multiple myeloma, rare bone disorders, pancreatic cancer, dermatomyositis, and polycythemia vera. 

The FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1, while Tauklarify (florquinitau F 18 injection/MK-6240) was approved as a PET imaging agent to identify tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer’s disease. 

The agency also granted accelerated approval to Zenbexus (iberdomide) plus daratumumab and hyaluronidase-fihj plus dexamethasone for certain patients with multiple myeloma who had received prior treatment. 

Other important August decisions included: 

• Pasatru (garetosmab-grts) for reducing new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva  

• Rasonque for patients with metastatic pancreatic ductal adenocarcinoma following at least one prior systemic therapy or for patients who are not candidates for multiagent systemic therapy  

• LISRAYA (brepocitinib) for adults with dermatomyositis  

• Mimrylo (rusfertide) for erythrocytosis in adults with polycythemia vera  

September 2026 

September continued the quarter’s momentum with approvals in rare diseases, oncology, spinal muscular atrophy, diabetes, glioma imaging, and cholangiocarcinoma. 

The FDA approved Zanvastro (50 mg, every three months, intrathecal injection) for pediatric and adult patients with AxD and granted Ionis a Rare Pediatric Disease Priority Review Voucher. 

The agency also granted accelerated approval to Etcamah plus a CDK4/6 inhibitor for HR-positive/HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation emerging during aromatase inhibitor plus CDK4/6 inhibitor therapy. The FDA simultaneously approved a ctDNA-based companion diagnostic for detecting ESR1 resistance mutations. 

Additional September approvals included: 

• Isembyld for patients aged two years and older with spinal muscular atrophy who are receiving an SMN2-targeted treatment  

• Pixclara (floretyrosine F 18) as an FET-PET imaging agent for glioma in patients aged one month and older  

• Onswik (insulin efsitora alfa-gobe) alongside diet and exercise to control blood glucose in adults with type 2 diabetes  

• Lyrfigtu for second-line treatment of cholangiocarcinoma with FGFR2 fusion or rearrangement  

• Atebrioz (100 mg, oral, once daily) to reduce total new heterotopic ossification volume in patients aged 12 years and older with fibrodysplasia ossificans progressiva  

The FDA also granted a Rare Pediatric Disease Priority Review Voucher to Incyte for Atebrioz. 

Additionally, Juvmo (tavapadon) received FDA approval for the treatment of Parkinson’s disease in adults, although no company press release was available at the time of compilation. 

Editor’s Take 

The Q3 approval landscape demonstrates that regulatory innovation is increasingly extending beyond traditional blockbuster indications. 

The quarter featured therapies and diagnostic technologies addressing rare diseases, molecularly defined cancers, neurological disorders, metabolic disease, ophthalmology, and treatment-response monitoring. 

The emergence of companion diagnostics and advanced imaging agents is particularly important. Approvals such as those involving tau PET and ctDNA-based testing illustrate how drug development and precision diagnostics are becoming increasingly interconnected. 

At the same time, several approvals in rare and ultra-rare diseases highlight the continued expansion of therapeutic options for populations that historically faced limited treatment choices. 

Conclusion: Q3 Signals a More Strategic Biopharma Era 

The third quarter of 2026 presented a biopharma industry operating on multiple fronts simultaneously. 

M&A brought consolidation. Licensing brought access to external innovation. FDA approvals brought new therapeutic and diagnostic options to patients. 

What connects these three trends is the growing importance of strategic differentiation. 

Companies are not simply pursuing more assets; they are pursuing assets that can provide access to new technologies, strengthen pipeline positions, expand into high-value therapeutic areas, or create new platforms for long-term growth. 

The quarter’s largest transactions also reveal how diverse the definition of biopharma innovation has become. Radiopharmaceuticals, AI-enabled diagnostics, ADCs, bispecific antibodies, siRNA, macrocycles, long-acting formulations, precision oncology, and advanced imaging all featured prominently across transactions and regulatory decisions. 

For investors, pharmaceutical companies, biotech leaders, and researchers, the message from Q3 is clear: the competitive landscape is increasingly being shaped by the ability to identify, access, develop, and scale differentiated innovation. 

As the industry moves into the final quarter of 2026, the focus will increasingly shift from the transactions and approvals of today to how these strategic moves translate into pipeline productivity, commercial growth, clinical differentiation, and ultimately better outcomes for patients.